title: Dexlansoprazole: delayed-release orally disintegrating tablets for the treatment of heartburn associated with non-erosive gastroesophageal reflux disease and the maintenance of erosive esophagitis.
abstract: Gastroesophageal reflux disease (GERD) is a common condition afflicting millions of patients, whose prevalence continues to rise owing to the aging population and increasing burden of comorbid conditions, such as obesity. Currently, the mainstay of therapy for GERD is treatment with proton pump inhibitors (PPIs), which have proven efficacy, safety, and tolerability. Despite this, a considerable number of patients have refractory symptoms to PPI therapy. Dexlansoprazole is a new addition to the class of PPIs, which has a unique dual delayed drug release system, which aims to address the current limitations of acid suppressive therapy by offering extended acid suppression and improved ease of administration. Areas covered: This manuscript covers the pharmacokinetics, pharmacodynamics, clinical efficacy, and regulatory approval of dexlansoprazole. Additionally, there is further discussion concerning the current market settings and the potential future impact of dexlansoprazole. Expert commentary: Overall, dexlansoprazole offers benefits in its ease of administration and proven efficacy in the healing, maintenance of erosive esophagitis, and symptomatic non-erosive GERD. Long-term, dexlansoprazole will likely find a niche market among patients who fail other acid suppressive therapy or who desire simplified administration for compliance concerns, but will likely come at a higher out of pocket expense than comparable generic PPIs.
authors: a Department of Internal Medicine , Eastern Virginia Medical School , Norfolk , VA , USA.
authors: Edward C
authors: EC
authors: Oldfield
authors: b Department of Internal Medicine, Division of Gastroenterology and Hepatology , Tulane University , New Orleans , LA , USA.
authors: Parth J
authors: PJ
authors: Parekh
authors: c Department of Internal Medicine, Division of Gastroenterology , Eastern Virginia Medical School , Norfolk , VA , USA.
authors: David A
authors: DA
authors: Johnson
keywords: Dexilant; Dexlansoprazole; erosive esophagitis; gastroesophageal reflux disease; non-erosive reflux disease; proton pump inhibitor